Background: Previous reports have shown an association between inflammatory diseases such as systemic lupus erythematosus or rheumatoid arthritis and the metabolic syndrome. Recent data demonstrate that psoriasis is an inflammatory disease, suggesting that psoriasis may be one of the components of the metabolic syndrome. Objective: To assess the association between psoriasis and the metabolic syndrome. Methods: A cross-sectional study was performed utilizing the database of the Clalit Health Services. Case patients were defined as patients with a diagnosis of psoriasis vulgaris. Controls were randomly selected from the list of Clalit Health Services enrollees. The proportions of components of the metabolic syndrome (ischemic heart disease, hypertension, diabetes, obesity and dyslipidemia) were compared between case and control patients by univariate analyses. χ2 tests were used to compare categorical parameters between the groups. Logistic and linear regression models served to measure the association between psoriasis and the metabolic syndrome. Results: The study included 16,851 patients with psoriasis and 48,681 controls. In the case group, there were 8,449 men (50.1%) and 8,402 women (49.9%), with a mean age of 42.7 years (SD = 20.3, range = 2–111). Diabetes mellitus was present in 13.8% of the patients with psoriasis as compared to 7.3% of the controls (p < 0.001). Hypertension occurred in 27.5% of the patients with psoriasis and in 14.4% of the controls (p < 0.001). Obesity was present in 8.4% of the patients with psoriasis as opposed to 3.6% of the controls (p < 0.001). Ischemic heart disease was observed in 14.2% of the patients with psoriasis as compared to 7.1% of the controls (p < 0.001). Multivariate models adjusting for age, gender and smoking status of the patients demonstrated that psoriasis was associated with the metabolic syndrome (OR = 1.3, 95% CI = 1.1–1.4), ischemic heart disease (OR = 1.1, 95% CI = 1.0–1.2), diabetes mellitus (OR = 1.2, 95% CI = 1.0–1.3), hypertension (OR = 1.3, 95% CI = 1.2–1.5) and obesity (OR = 1.7, 95% CI = 1.5–1.9). Limitations: The study is designed as a case-control study, thus an association alone was proven and not causality. Conclusion: Our findings demonstrate a possible association between psoriasis and the metabolic syndrome. Appropriate treatment of the metabolic syndrome may be an important part of the management of patients with psoriasis.

Keywords:
Metabolic syndrome, Psoriasis
1.
Lopez-Candales A: Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. J Med 2001;32:283–300.
2.
Timar O, Sestier F, Levy E: Metabolic syndrome X: a review. Can J Cardiol 2000;16:779–789.
3.
Zambon A, Pauletto P, Crepaldi G: Review article: the metabolic syndrome – a chronic cardiovascular inflammatory condition. Aliment Pharmacol Ther 2005;22(suppl 2):20–23.
4.
Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, et al: Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006;33:539–545.
5.
Dessein PH, Stanwix AE, Joffe BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002;4:R5.
6.
Rhew EY, Ramsey-Goldman R: Premature atherosclerotic disease in systemic lupus erythematosus – role of inflammatory mechanisms. Autoimmun Rev 2006;5:101–105.
7.
Chamian F, Krueger JG: Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol 2004;16:331–337.
8.
Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F: The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004;150:917–928.
9.
Terui T, Ozawa M, Tagami H: Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol 2000;9:1–10.
10.
Dellavalle RP, Johnson KR: Do smoking, obesity, and stress cause psoriasis? J Invest Dermatol 2005;125:vi–vii.
11.
Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982–986.
12.
Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al: Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527–1534.
13.
Horrobin DF: Low prevalences of coronary heart disease (CHD), psoriasis, asthma and rheumatoid arthritis in Eskimos: are they caused by high dietary intake of eicosapentaenoic acid (EPA), a genetic variation of essential fatty acid (EFA) metabolism or a combination of both? Med Hypotheses 1987;22:421–428.
14.
Lindegard B: Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298–304.
15.
Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al: Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225–230.
16.
Alberti KG, Zimmet P, Shaw J: The metabolic syndrome – a new worldwide definition. Lancet 2005;366:1059–1062.
17.
Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S: An Italian study on psoriasis and depression. Dermatology 2006;212:123–127.
18.
Schmitt-Egenolf M: Psoriasis therapy in real life: the need for registries. Dermatology 2006;213:327–330.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.